Mastocytosis

Lancet

Volumn 349, Issue 9062, 1997, Pages 1379-1385

  Golkar, Linda ^a   Bernhard, Jeffrey D ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CROMOGLYCATE DISODIUM;

CELL PROLIFERATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; HUMAN; MAST CELL; MASTOCYTOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SKIN DISEASE; SYMPTOM;

EID: 0030956444     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07056-0     Document Type: Review

References (30)

1. Sagher F, Even-Paz Z. Mastocytosis and the mast cell. Chicago: Year Book Medical Publishers, 1967.
2. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991; 146: 1410-15.
3. Longley BJ, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993; 328: 1302-07.
4. Funasaka Y, Boulton T, Cobb M, et al. C-kit kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992; 3: 197-209.
5. Longley J. Is mastocytosis a mast cell neoplasia or a reactive hyperplasia? Clues from the study of mast cell growth factor. Ann Med 1994; 26: 115-16.
6. Longley BJ, Tyrrell L, Lu S-Z, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312-14.
7. Metcalfe DD. Conclusions. Clinical advances in mastocytosis: an interdisciplinary round table discussion. J Invest Dermatol 1991; 96 (suppl): 64S-65S.
8. Soter NA. The skin in mastocytosis. J Invest Dermatol 1991; 96 (suppl): 32S-39S.
9. Roberts LJ, Fields JP, Gates JA. Mastocytosis without urticaria pigmentosa: a frequently unrecognized cause of recurrent syncope. Trans Assoc Am Phys 1982; 95: 36-41.
10. Travis WD, Li C-Y, Bergstralh EJ, et al. Systemic mast cell disease: analysis of 58 cases and literature review. Medicine 1988; 67: 345-68.
11. Travis WD, Li C-Y, Hoagland HC, Travis LB, Banks PM. Mast cell leukaemia: report of a case and review of the literature. Mayo Clin Proc 1986; 61: 957-66.
12. Webb TA, Li C-Y, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Career 1982; 49: 927-38.
13. Parwaresch MR, Horny H-P, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985; 179 (suppl): 439-61.
14. Roberts LJ. Carcinoid syndrome and disorders of systemic mast-cell activation including systemic mastocytosis. Endocrinol Metab Clin North Am 1988; 17: 415-36.
15. Wilkin JK. The red face: flushing disorders. Clin Dermatol 1993; 11: 211-32.
16. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. Ann Allergy 1994; 73: 197-202.
17. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's hospital. J Invest Dermatol 1991; 96 (suppl): 5S-14S.
18. Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis. Gastroenterology 1988; 95: 657-67.
19. Mican JM, Bisceglie AM, Fong T-L, et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995; 22: 1163-70.
20. Travis WD, Li C-Y, Yam LT, et al. Significance of systemic mast cell disease with associated hematological disorders. Cancer 1988; 62: 965-72.
21. Garriga MM, Friedman MM, Metcalfe DD. A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol 1988; 82: 425-32.
22. Demis DJ, Walton MD, Higdon RS. Histaminuria in urticaria pigmentosa: clinical study and review of recent literature with definition of the mastocytosis syndrome. Arch Dermatol 1961; 83: 127-38.
23. Keyzer JJ, De Monchy JGR, Van Doormaal JJ, et al. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983; 309: 1603-05.
24. Granerus G, Olafsson JH, Roupe G. Studies on histamine metabolism in mastocytosis. J Invest Dermatol 1983; 80: 410-16.
25. Kors JW, Van Doormaal JJ, Breukelman H, et al. Long-term follow-up of indolent mastocytosis in adults. J Intern Medicine 1996; 239: 157-64.
26. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systematic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-26.
27. Morrow JD, Guzzo C, Lazarus G, Gates JA, Roberts LJ. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995; 104: 937-40.
28. Bernhard JD. Endocrine itches. In: Itch: mechanisms and management of pruritus. New York: McGraw-Hill, 1994.
29. Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med. 1979; 301: 465-69.
30. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992; 326: 619-23.